Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Another Phase III Study Supports Avastin Expansion To Ovarian Cancer

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.

You may also be interested in...



Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT

The latest drug development news and highlights from our US FDA Performance Tracker.

FDA Finally Approves Avastin In First-Line Ovarian Cancer

Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.

Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed

Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By